Halozyme Therapeutics, Inc.

Company overview. Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a San Diego, California–headquartered biopharmaceutical company founded in 1998, with additional offices and an operations facility in Ewing, NJ and Minnetonka, MN. It is an independent public company (no parent); operating subsidiaries include Halozyme, Inc. and Antares Pharma. Public filings put headcount at roughly 350–423 employees (2024–2025) and total revenue at about $1.02 billion for FY2024 and about $1.40 billion for FY2025, with market data sources placing market capitalization in the multi-billion-dollar range.

Products / operations. Halozyme is an operating company whose core asset is ENHANZE, a drug-delivery platform built on its proprietary recombinant human hyaluronidase enzyme rHuPH20, which enables subcutaneous administration of drugs otherwise given intravenously. It licenses ENHANZE to biopharma partners and earns royalties, milestones and license fees, and also sells bulk rHuPH20. Partnered products include J&J's DARZALEX FASPRO, Roche's Phesgo, argenx's VYVGART Hytrulo, and more recent subcutaneous launches (TECENTRIQ SC, OCREVUS SC, RYBREVANT SC, Opdivo Qvantig). It also markets two proprietary products — Hylenex recombinant and XYOSTED (testosterone auto-injector, acquired via the 2022 Antares Pharma deal) — and develops drug-device combination and high-concentration biologic formulation technologies.

Patent-litigation posture. In the tracked data Halozyme appears in exactly one matter and only as a defendant: Merck Sharp & Dohme LLC v. Halozyme, Inc. et al., filed 2025-02-04 at the USPTO Patent Trial and Appeal Board. It has zero plaintiff-side appearances in our data. This is a defensive post-grant challenge venue, not a district court filing, so there is no plaintiff-friendly district clustering to note. The profile is consistent with an operating company being attacked on its patents rather than an assertion entity.

Notable context. The PTAB matter is part of a wider dispute over Halozyme's modified-PH20 ("MDASE") patents after Merck developed subcutaneous pembrolizumab using Alteogen's ALT-B4 enzyme; Merck filed a series of PGR petitions (including PGR2025-00003, -00004, -00006, -00017 and others) against Halozyme patents. Halozyme separately filed an infringement action against Merck in the District of New Jersey (2:25-cv-03179), which is not reflected in our tracked case list. No view is expressed on the merits of any proceeding.